JP2016500682A5 - - Google Patents

Download PDF

Info

Publication number
JP2016500682A5
JP2016500682A5 JP2015537240A JP2015537240A JP2016500682A5 JP 2016500682 A5 JP2016500682 A5 JP 2016500682A5 JP 2015537240 A JP2015537240 A JP 2015537240A JP 2015537240 A JP2015537240 A JP 2015537240A JP 2016500682 A5 JP2016500682 A5 JP 2016500682A5
Authority
JP
Japan
Prior art keywords
amino acid
pharmaceutical composition
composition according
glp
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2015537240A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016500682A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2013/071618 external-priority patent/WO2014060472A1/en
Publication of JP2016500682A publication Critical patent/JP2016500682A/ja
Publication of JP2016500682A5 publication Critical patent/JP2016500682A5/ja
Withdrawn legal-status Critical Current

Links

JP2015537240A 2012-10-17 2013-10-16 経口ペプチドデリバリーのための脂肪酸アシル化アミノ酸 Withdrawn JP2016500682A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP12188872.1 2012-10-17
EP12188872 2012-10-17
US201261715416P 2012-10-18 2012-10-18
US61/715,416 2012-10-18
PCT/EP2013/071618 WO2014060472A1 (en) 2012-10-17 2013-10-16 Fatty acid acylated amino acids for oral peptide delivery

Publications (2)

Publication Number Publication Date
JP2016500682A JP2016500682A (ja) 2016-01-14
JP2016500682A5 true JP2016500682A5 (enExample) 2016-12-08

Family

ID=47049065

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015537240A Withdrawn JP2016500682A (ja) 2012-10-17 2013-10-16 経口ペプチドデリバリーのための脂肪酸アシル化アミノ酸

Country Status (5)

Country Link
US (1) US20150273069A1 (enExample)
EP (1) EP2908844A1 (enExample)
JP (1) JP2016500682A (enExample)
CN (1) CN104717972A (enExample)
WO (1) WO2014060472A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015162195A1 (en) * 2014-04-23 2015-10-29 Novo Nordisk A/S Fatty acid acylated amino acids for oral peptide delivery
JP6910950B2 (ja) 2015-01-12 2021-07-28 エンテリス・バイオファーマ・インコーポレイテッドEnteris Biopharma,Inc. 固形経口剤形
CN107205948B (zh) * 2015-01-29 2021-12-14 诺和诺德股份有限公司 包含glp-1激动剂和肠溶衣的片剂
EP3250190A1 (en) * 2015-01-29 2017-12-06 Novo Nordisk A/S Pharmaceutical composition for oral glp-1 administration comprising a tablet core and immediate release coating
US10588974B2 (en) 2016-04-22 2020-03-17 Receptor Holdings, Inc. Fast-acting plant-based medicinal compounds and nutritional supplements
EA201892396A1 (ru) 2016-12-02 2019-04-30 Ресептор Лайф Сайенсиз, Инк. Быстродействующие растительные лекарственные соединения и биологически активные добавки
CN111050750B (zh) * 2017-08-24 2024-09-24 诺和诺德股份有限公司 Glp-1组合物及其用途
PE20211492A1 (es) * 2018-10-26 2021-08-11 Novo Nordisk As Composiciones estables de semaglutida y usos de las mismas
JP7566336B2 (ja) 2018-11-19 2024-10-15 スポーク・サイエンシズ・インコーポレイテッド カンナビノイド由来組成物の吸収変動を低減するn-アシル化脂肪アミノ酸
JP7761567B2 (ja) 2020-02-18 2025-10-28 ノヴォ ノルディスク アー/エス 医薬製剤
WO2022049310A1 (en) * 2020-09-07 2022-03-10 Cyprumed Gmbh Improved pharmaceutical formulations of glp-1 receptor agonists
EP4222176A4 (en) 2020-09-30 2024-02-28 Beijing QL Biopharmaceutical Co., Ltd. POLYPEPTIDE CONJUGATES AND METHODS OF USE
CN114272511B (zh) * 2021-01-12 2023-08-01 广州新济药业科技有限公司 司美格鲁肽可溶性微针贴片及其制备方法
EP4180060A1 (en) 2021-11-15 2023-05-17 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
EP4299057A1 (en) 2022-06-30 2024-01-03 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
EP4433093A1 (en) 2021-11-15 2024-09-25 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
JP2025508982A (ja) * 2022-03-03 2025-04-10 サイプルメド ゲーエムベーハー 治療用ペプチドおよびタンパク質の改善された経口医薬製剤
KR20240163717A (ko) 2022-03-30 2024-11-19 베이징 큐엘 바이오파마슈티컬 컴퍼니 리미티드 폴리펩티드 접합체의 액체 약학 조성물 및 그의 사용 방법
KR20250144708A (ko) * 2024-03-27 2025-10-13 한국과학기술연구원 올리고감마글루탐산 유도체 기반의 신규한 지질 및 이를 포함하는 지질나노입자와 이의 용도

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5629020A (en) * 1994-04-22 1997-05-13 Emisphere Technologies, Inc. Modified amino acids for drug delivery
DK39892D0 (da) 1992-03-25 1992-03-25 Bernard Thorens Peptid
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
CA2264243C (en) 1996-08-30 2004-10-05 Novo Nordisk A/S Glp-1 derivatives
EP1062240B1 (en) 1998-02-27 2010-04-28 Novo Nordisk A/S N-terminally modified glp-1 derivatives
WO1999043708A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
WO1999043341A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-1 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
AU2610699A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S Derivatives of glp-1 analogs
US6656499B1 (en) * 1999-11-12 2003-12-02 Pharmaderm Laboratories, Ltd. Composition for transdermal and dermal administration of interferon-α
FR2828102B1 (fr) * 2001-03-28 2004-07-09 Ifc Sa Utilisation des lipoaminoacides dans une composition pharmaceutique comme promoteur et systeme disperse a usage pharmaceutique contenant de tels composes
KR101241862B1 (ko) 2003-09-19 2013-03-13 노보 노르디스크 에이/에스 신규 glp-1 유도체
CA2550050A1 (en) 2003-12-18 2005-06-30 Novo Nordisk A/S Novel glp-1 analogues linked to albumin-like agents
BRPI0417717A (pt) 2003-12-18 2007-04-03 Novo Nordisk As composto, composição farmacêutica, e, uso de um composto
US20060286129A1 (en) * 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
WO2006003781A1 (ja) 2004-06-30 2006-01-12 Pioneer Corporation バックアップ装置および車載機器
CA2572770A1 (en) 2004-07-08 2006-01-19 Novo-Nordisk A/S Polypeptide protracting tags comprising a tetrazole moiety
US7544714B2 (en) * 2004-07-16 2009-06-09 University Of Massachusetts Lipid-amino acid conjugates and methods of use
WO2006037811A2 (en) 2004-10-07 2006-04-13 Novo Nordisk A/S Protracted exendin-4 compounds
AU2006224537A1 (en) 2005-03-18 2006-09-21 Novo Nordisk A/S Extended GLP-1 compounds
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
WO2008023050A1 (en) 2006-08-25 2008-02-28 Novo Nordisk A/S Acylated exendin-4 compounds
EP2679597A1 (en) 2007-09-05 2014-01-01 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
CN101842109B (zh) 2007-09-05 2014-01-29 诺沃-诺迪斯克有限公司 用a-b-c-d-衍生的肽和它们的治疗用途
WO2009030774A1 (en) 2007-09-05 2009-03-12 Novo Nordisk A/S Truncated glp-1 derivatives and their therapeutical use
US20100317057A1 (en) 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
JP6030630B2 (ja) * 2011-04-14 2016-11-24 ノヴォ ノルディスク アー/エス 経口ペプチド送達のための脂肪酸アシル化アミノ酸

Similar Documents

Publication Publication Date Title
JP2016500682A5 (enExample)
JP6294868B2 (ja) 液体水性組成物
JP2013518115A5 (enExample)
ES2558155T3 (es) Compuestos que muestran actividad antagonista de glucacón y agonista de GLP-1
ES2528599T3 (es) Análogos truncados de un polipéptido insulinotrópico dependiente de glucosa
JP2014512366A5 (enExample)
EA201170337A1 (ru) Стабильная твердая композиция полипептидного агониста gc-c рецептора, приемлемая для перорального введения
JP2013155195A5 (enExample)
WO2010051541A3 (en) Compositions containing delta-9-thc-amino acid esters and process of preparation
RU2012101274A (ru) Соединения глюкагона, активные в отношении рецептора gip
JP2018505146A5 (enExample)
PE20241305A1 (es) Analogos de amilina
WO2009011544A3 (en) Insulinotropic peptide derivative wherein its n-terminal amino acid is modified
WO2012054500A3 (en) Compositions for drug administration
PE20120563A1 (es) Construcciones novedosas de proteina del virus de papiloma humano (hpv) y su uso en la prevencion de la enfermedad por el hpv
RU2020120797A (ru) Пептидные композиции
IL276170B1 (en) Modified lipidated relaxin b chain peptides and their therapeutic use
CA2776302A1 (en) Neuropeptide-2 receptor (y-2r) agonists
WO2011038900A3 (en) Peptide analogues of glucagon for diabetes therapy
EA201390998A1 (ru) Препарат фторуглеродсвязанных пептидов
WO2012174397A3 (en) Anti-inflammatory pharmaceutical products
WO2007135117A3 (en) Soluble, stable insulin-containing formulations
WO2016047797A1 (ja) 注射用医薬組成物
JP2009533355A5 (enExample)
CN116888146A (zh) 胰高血糖素样肽-1受体拮抗剂